Literature DB >> 17998673

Hyperthermia today: electric energy, a new opportunity in cancer treatment.

Giammaria Fiorentini1, Andras Szasz.   

Abstract

Hyperthermia is an ancient, but nowadays rapidly developing treatment method in tumor-therapy. Its new paradigm applied in the electro-hyperthermia (oncothermia), which provides energy by means of electric-field and produces non-equilibrium thermal situation in the tissue. The temperature gradients formed in stationary conditions, destroy the membrane of the malignant cells and selectively eliminate the cancer tissue. The characteristic control parameter is the absorbed energy-dose, which is partly used to make the distortions, partly to increase the temperature of the target. This type of technique could be applied for some tumor sites, including brain, soft tissues, liver and abdominal masses, pancreatic cancer, head and neck tumors as well.

Entities:  

Mesh:

Year:  2006        PMID: 17998673     DOI: 10.4103/0973-1482.25848

Source DB:  PubMed          Journal:  J Cancer Res Ther        ISSN: 1998-4138            Impact factor:   1.805


  18 in total

1.  DNA fragmentation and caspase-independent programmed cell death by modulated electrohyperthermia.

Authors:  N Meggyeshazi; G Andocs; L Balogh; P Balla; G Kiszner; I Teleki; A Jeney; T Krenacs
Journal:  Strahlenther Onkol       Date:  2014-02-22       Impact factor: 3.621

2.  Principles of cancer therapy: oncogene and non-oncogene addiction.

Authors:  Ji Luo; Nicole L Solimini; Stephen J Elledge
Journal:  Cell       Date:  2009-03-06       Impact factor: 41.582

3.  Upregulation of heat shock proteins and the promotion of damage-associated molecular pattern signals in a colorectal cancer model by modulated electrohyperthermia.

Authors:  Gabor Andocs; Nora Meggyeshazi; Lajos Balogh; Sandor Spisak; Mate Elod Maros; Peter Balla; Gergo Kiszner; Ivett Teleki; Csaba Kovago; Tibor Krenacs
Journal:  Cell Stress Chaperones       Date:  2014-06-29       Impact factor: 3.667

4.  Strong synergy of heat and modulated electromagnetic field in tumor cell killing.

Authors:  Gabor Andocs; Helmut Renner; Lajos Balogh; Laszlo Fonyad; Csaba Jakab; Andras Szasz
Journal:  Strahlenther Onkol       Date:  2009-02-25       Impact factor: 3.621

Review 5.  Radiotherapy in conjunction with superficial and intracavitary hyperthermia for the treatment of solid tumors: survival and thermal parameters.

Authors:  S Triantopoulou; E Efstathopoulos; K Platoni; N Uzunoglou; N Kelekis; V Kouloulias
Journal:  Clin Transl Oncol       Date:  2012-11-21       Impact factor: 3.405

6.  Fever-range hyperthermia vs. hypothermia effect on cancer cell viability, proliferation and HSP90 expression.

Authors:  Dimitra Kalamida; Ilias V Karagounis; Achilleas Mitrakas; Sofia Kalamida; Alexandra Giatromanolaki; Michael I Koukourakis
Journal:  PLoS One       Date:  2015-01-30       Impact factor: 3.240

Review 7.  Local hyperthermia in head and neck cancer: mechanism, application and advance.

Authors:  Shiyu Gao; Min Zheng; Xiaohua Ren; Yaling Tang; Xinhua Liang
Journal:  Oncotarget       Date:  2016-08-30

8.  In vitro comparison of conventional hyperthermia and modulated electro-hyperthermia.

Authors:  Kai-Lin Yang; Cheng-Chung Huang; Mau-Shin Chi; Hsin-Chien Chiang; Yu-Shan Wang; Chien-Chung Hsia; Gabor Andocs; Hsin-Ell Wang; Kwan-Hwa Chi
Journal:  Oncotarget       Date:  2016-12-20

9.  Sorafenib and locoregional deep electro-hyperthermia in advanced hepatocellular carcinoma: A phase II study.

Authors:  Gennaro Gadaleta-Caldarola; Stefania Infusino; Ida Galise; Girolamo Ranieri; Gianluca Vinciarelli; Vito Fazio; Rosa Divella; Antonella Daniele; Gianfranco Filippelli; Cosmo Damiano Gadaleta
Journal:  Oncol Lett       Date:  2014-07-24       Impact factor: 2.967

10.  Clinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21/28 days regimen in the treatment of recurrent glioblastoma: a retrospective analysis of a two-centre German cohort trial with systematic comparison and effect-to-treatment analysis.

Authors:  Sergey V Roussakow
Journal:  BMJ Open       Date:  2017-11-03       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.